3570-93-2 Usage
Description
AIDS124927 is a chemical compound with significant potential as an anti-HIV agent, characterized by its ability to inhibit the growth of HIV, the virus responsible for causing AIDS. It targets the virus and impedes its replication process, showing potent inhibitory activity against HIV-1 protease, a key enzyme for viral replication and dissemination within the host.
Uses
Used in Pharmaceutical Industry:
AIDS124927 is used as an anti-HIV agent for its capacity to inhibit the replication of the HIV virus. Its potent inhibitory activity against HIV-1 protease makes it a promising candidate for further research and development into new treatments for HIV/AIDS.
Used in HIV/AIDS Research:
AIDS124927 is utilized in research settings to study its effects on HIV and to explore its potential as a therapeutic intervention. AIDS124927's ability to target and block the virus's replication mechanisms is of particular interest, as it could contribute to the advancement of more effective treatments for HIV/AIDS.
Used in Drug Development:
AIDS124927 serves as a lead compound in the development of new antiviral drugs. Its discovery and study may pave the way for the creation of novel pharmaceuticals that can combat HIV more effectively, offering improved outcomes for patients affected by the disease.
Check Digit Verification of cas no
The CAS Registry Mumber 3570-93-2 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 3,5,7 and 0 respectively; the second part has 2 digits, 9 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 3570-93:
(6*3)+(5*5)+(4*7)+(3*0)+(2*9)+(1*3)=92
92 % 10 = 2
So 3570-93-2 is a valid CAS Registry Number.
InChI:InChI=1/C6H9N3O3/c10-7-4-2-1-3-5(8-11)6(4)9-12/h7,10-11H,1-3H2/b8-5-
3570-93-2Relevant articles and documents
FUROXAN-BASED COMPOUNDS AND USES THEREOF
-
, (2019/07/30)
Described herein are compounds of the formula (I), as well as pharmaceutical compositions comprising such compounds, and methods for using such compounds/pharmaceutical compositions for treating neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, Huntington's disease, and multiple sclerosis (MS).
